-
1 month ago | 
patientcareonline.com | Elizabeth Swanson |Sydney Jennings
Herpes zoster, aka shingles, is not just for grandparents anymore, Elizabeth Swanson, MD, said during her presentation during the "Big Rashes in Little Patients" session at the 2025 American Academy of Dermatology Annual Meeting in Orlando. More children are being diagnosed with shingles, particularly immunocompetent children, Dr Swanson said at the meeting. Why the uptick?
-
1 month ago | 
patientcareonline.com | Elizabeth Swanson |Sydney Jennings
2 Commerce Drive Cranbury, NJ 08512
-
2 months ago | 
caledonianrecord.com | Elizabeth Swanson
When Moath al-Alwi left Guantánamo Bay for resettlement in Oman, accompanying him on his journey was a cache of artwork he created during more than two decades of detention. kAmp=\p=H: H2D 56E2:?66 ?F>36C “_ag” – 2? :?5:42E:@? E92E 96 H2D @?6 @7 E96 7:CDE E@ 2CC:G6 2E E96 &]$] >:=:E2CJ AC:D@? @77 rF32 27E6C :E @A6?65 :? y2?F2CJ a__a] w:D 56A2CEFC6 7C@> E96 56E6?E:@? 46?E6C @?
-
Oct 21, 2024 | 
consultantlive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
-
Oct 21, 2024 | 
hcplive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
OpinionVideoOctober 21, 2024Author(s):, Oral JAK inhibitors provide a convenient alternative to injectable biologics, potentially enhancing patient adherence in maintenance therapy. These inhibitors target specific inflammatory pathways, offering a tailored approach to managing autoimmune conditions. In rescue treatment, oral JAK inhibitors can quickly modulate immune responses, benefiting patients during disease flares.
-
Oct 21, 2024 | 
hcplive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
OpinionVideoOctober 21, 2024Author(s):, Novel oral systemic agents are being developed, targeting specific pathways in atopic dermatitis pathophysiology for improved efficacy and safety. Personalized medicine approaches and biomarkers are expected to enhance treatment outcomes by tailoring therapies to individual patient profiles. Future treatments aim to provide better disease control, reduce side effects, and improve patient quality of life.
-
Oct 21, 2024 | 
consultantlive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
-
Oct 16, 2024 | 
hcplive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
OpinionVideoOctober 16, 2024Author(s): Patients frequently discuss treatment breaks, influenced by individual treatment responses and personal circumstances. Monitoring during treatment breaks involves regular follow-ups to assess disease activity and manage potential flares. Education and counseling emphasize adherence, recognizing flare signs, and understanding rescue treatments.
-
Oct 16, 2024 | 
consultantlive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
Advances in Oral Systemic Treatments for Management of Atopic Dermatitis - Episode 12Published on: , , , Medical experts rate dermatologists’ comfort with switching to JAK inhibitors and describe how frequently to switch patients from biologics to JAK inhibitors, including their treatment strategy for this population. Video content above is prompted by the following:How would you rate dermatologists’ comfort in switching to a JAK inhibitor?
-
Oct 16, 2024 | 
hcplive.com | Raj Chovatiya |George Han |Elizabeth Swanson |Peter Lio
OpinionVideoOctober 16, 2024Author(s): Dermatologists' comfort with JAK inhibitors is influenced by familiarity and patient-specific factors, affecting their willingness to switch treatments. Switching from biologics to JAK inhibitors is determined by treatment response, side effects, and patient preferences. Treatment strategies involve assessing disease severity, treatment history, and weighing risks versus benefits of JAK inhibitors.
